(P203) New Horizons in T2D Management and Cardiorenal Risk Reduction: A Pharmacotherapeutic Update

This poster will provide an update on FDA-approved and potential therapeutic agents to be used in managing diabetes and/or its associated complications, e.g., dasiglucagon, SGLT2 inhibitors, efpeglenatide, tirzepatide, finerenone, and insulin icodec. Safety and efficacy data from published trials will be included for each of these agents, as well as recent diabetes treatment guidelines focusing on pharmacotherapy recommendations in reducing cardiorenal risks in those with type 2 diabetes. Recent pooled data on GLP-1 receptor agonists and SGLT2 inhibitors in select subpopulations will be highlighted.